10X Genomics Inc

10X Genomics Inc（TXG）股票分析

$61.650

+1.714 (+2.78%)收盤時

Loading chart…
High
63.490
Open
60.240
VWAP
61.52
Vol
1.60M
Mkt Cap
2.38B
Low
59.410
Amount
98.73M
EV/EBITDA, TTM
-8.95

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

www.10xgenomics.com

估值指標

The current forward P/E ratio for 10X Genomics Inc (TXG) is -9.54, compared to its 5-year average forward P/E of -59.30.

Forward P/E

Fair
5Y Average P/E
-59.30
Current P/E
-9.54
高估
48.03
低估
-166.62

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-576.66
Current EV/EBITDA
-8.95
高估
1421.23
低估
-2574.56

Forward P/S

Fair
5Y Average P/S
9.21
Current P/S
2.27
高估
16.51
低估
1.91

Alphio AI Price Scenarios for TXG

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TXG

$7.67

情境價格

B

Base

Base · 50%TXG

$7.57

情境價格

B

Bear

Bear · 25%TXG

$6.64

情境價格

Whales holding TXG

B

Baker Steel Capital Managers LLP

+ HoldingTXG

+19.46%

3M Return

S

Sprott Inc.

+ HoldingTXG

+18.16%

3M Return

A

ARK Investment Management LLC

+ HoldingTXG

+11.64%

3M Return

K

Konwave AG (Gold 2000)

+ HoldingTXG

+11.17%

3M Return

H

Hillsdale Investment Management Inc.

+ HoldingTXG

+10.89%

3M Return

H

Harvard Management Company, Inc.

+ HoldingTXG

+6.13%

3M Return

事件時間軸

2026-08-28 (ET)

15:00:00

10x Genomics Awarded $4.8M for Parse Biosciences Infringement

2026-08-06 (ET)

19:00:00

Stock Futures Mixed as Doximity Soars 83.93%

2026-07-29 (ET)

09:30:00

10x Genomics Partners with Lausanne University Hospital to Advance Cancer Diagnostics Research

2026-06-17 (ET)

09:30:00

10x Genomics Collaborates with Cleveland Clinic on Bladder Cancer Diagnostics Research

2026-06-09 (ET)

09:20:00

10x Genomics Acquires New Company

Show More Events

資訊

Show More News

TXG FAQ — answered by Alphio AI

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始